Prophylix Pharma AS

Prophylix Pharma develops a prophylactic treatment for the condition Neonatal Alloimmune Trombocytopenia (NAIT) in newborns. NAIT is caused by tissue incompatibility between a mother and her child and causes severe illness and often mortality in newborns. The planned treatment will be administered as a single dose injection to the mother immediately after delivery and the treatment has the potential to prevent development of NAIT in subsequent pregnancies. The technological basis of Prophylix Pharma comes from research at The University Hospital of North Norway and Ullevål University Hospital.  Sarsia Seed is invested in Prophylix Pharma AS through a co-investment with the seed fund Norinnova Invest AS and Trond Mohn Foundation.